| Published Date | Report Code | No. of Pages | Report Format |
| July – 2020 | AMR- 12003 | 110 | PDF / Excel |
Increasing awareness of glaucoma and rising demand for drugs made for the treatment of glaucoma are some of the major trends that can be observed in the global glaucoma eye drops market. Glaucoma can be majorly seen in people above the age of 40 and it may be asymptomatic. According to a recent survey by Glaucoma Research Foundation, 74% of over 1,000 people interviewed said they have their eyes examined at least every two years. 61% of those (less than half of all adult Americans) are receiving a dilated eye exam (the best and most effective way to detect glaucoma). 16% of African Americans were unfamiliar with glaucoma. 9% of Caucasians were unfamiliar with glaucoma.
A few novel glaucoma eye drops have been affirmed by administrative bodies in various nations and significant players in the market have propelled different novel and inventive glaucoma eye drops. Quick endorsements and dispatches of novel products in the market are relied upon to be a significant driver for the development of the glaucoma eye drops market. For instance, in March 2019, the U.S. Food and Drug Administration (USFDA) approved Aerie Pharmaceuticals’ Rocklatan a netarsudil and latanoprost ophthalmic solution for the treatment of open-angle glaucoma.
Nevertheless, glaucoma is a sickness that can’t be cured, yet it tends to be controlled. Eye drops, pills, laser strategies, and surgeries are utilized to forestall or slow further harm from happening. Glaucoma is an irreversible sickness, and the broad R&D exercises make the medication over the top expensive which is anticipated to hamper the glaucoma eye drops market growth during the years to come.
The global glaucoma eye drops market size was esteemed at USD 1.2 billion in 2019 and is anticipated to expand at a CAGR of 6.5% during the forecast period 2019-2028. The rising prevalence and incidence of eye-related diseases are major factor proliferating the growth of glaucoma eye drops market. Glaucoma cases are up surging every year across the globe and account for over 10 million visits to physicians every year. According to world health organization (WHO), glaucoma is the second most common cause of blindness worldwide with more than 70 million people affected by it, and this figure is expected to grow to 111 million by 2040. The most common type of glaucoma are primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). According to world health organization (WHO), glaucoma is responsible for approximately 5 million blind which is 15% of total world blindness.
The global glaucoma eye drops market is anticipated to grow significantly on the back of a high number of populations are impacted by this, and increasing number of cases worldwide. The rising government initiatives and drug approvals for prevention of glaucoma-related blindness are further bolstering the growth of the global glaucoma eye drops market. The market for glaucoma eye drops is projected to cross US$ 6 billion by 2028.
Based on disease perspective in glaucoma eye drops industry, glaucoma eye drops can be classified into open-angle glaucoma and angle-closure glaucoma. In 2019, open-angle glaucoma was the most common for contributing more than 80% of market revenue. According to American Academy of Ophthalmology, Primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness worldwide. This is anticipated to bolster the growth of the segment.
In addition, according to American Academy of Ophthalmology, a hospital-based survey of glaucoma in Ghana reported that the most common form of glaucoma was primary open-angle glaucoma (44.2%). People in their 70s have a 3 to 8 times higher prevalence of POAG. As the population ages, the total number of glaucoma patients will continue to rise.
North America dominated the global glaucoma eye drops market accounting for a market share of more than 30% of market revenue. This can be attributed to rising number of glaucoma cases and increasing number of product launches for its treatment. For instance, According to a recent study, more than 3 million Americans are living with glaucoma, 2.7 million of those—aged 40 and more—are affected by its most common form, open-angle glaucoma. Blindness or low vision affects 3.3 million Americans age 40 and over. Glaucoma costs the U.S. economy $2.86 billion every year in direct costs and productivity losses.
Asia Pacific region is anticipated to register fastest growth during the forecast period. This can be associated with rising prevalence of glaucoma in the region with more than 90% of cases remaining undiagnosed. For instance, according to world health organization, In India, glaucoma is the leading cause of irreversible blindness with at least 12 million people affected, and nearly 1.2 million people blind from the disease.
Noticeable players within the market are
The players of glaucoma eye drops industry are focusing majorly on developing and launching more advanced products with more features to gain a competitive edge in the market. Strategies such as partnerships, new product development, licensing agreements, and other legally binding agreements are being reported by major players to become the market leader. For instance, in June 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension.
This report bifurcates glaucoma eye drops revenue opportunities at worldwide, territorial, and national levels and gives an investigation of the most recent industry patterns in each of the sub-segments during the estimated period. For the reason of this ponder, Alchemy Market Research has sectioned the worldwide glaucoma eye drops market report on the premise of drug type strategy, disease strategy, sales channel strategy, and regional analysis:
Drug Type Perspective (Revenue in USD Billion)
Disease Perspective (Revenue in USD Billion)
Sales Channel Perspective (Revenue in USD Billion)
Regional Perspective (Revenue in USD Billion)
Chapter 1. Executive Summary
Chapter 2. Market Introduction
Chapter 3. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints
Chapter 4. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
Chapter 5. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Drug Type
5.1. Beta Blockers
5.2. Alpha Agonists
5.3. Carbonic Anhydrase Inhibitors
5.4. Prostaglandin analogs
5.5. Combined medications
5.6. Others
Chapter 6. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Disease
6.1. Open Angle Glaucoma
6.2. Angle Closure Glaucoma
Chapter 7. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Sales Channel
7.1. Online
7.2. Retail
7.3. Hospital Pharmacy
Chapter 8. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Region
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. Latin America
8.5. Middle East & Africa
Chapter 9. North America Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
9.1. North America Glaucoma Eye Drops Market– By Drug Type
9.1.1. Beta Blockers
9.1.2. Alpha Agonists
9.1.3. Carbonic Anhydrase Inhibitors
9.1.4. Prostaglandin analogs
9.1.5. Combined medications
9.1.6. Others
9.2. North America Glaucoma Eye Drops Market– By Disease
9.2.1. Open Angle Glaucoma
9.2.2. Angle Closure Glaucoma
9.3. North America Glaucoma Eye Drops Market– By Sales Channel
9.3.1. Online
9.3.2. Retail
9.3.3. Hospital Pharmacy
9.4. North America Glaucoma Eye Drops Market– By Country
9.4.1. U.S.
9.4.2. Canada
Chapter 10. Europe Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
10.1. Europe Glaucoma Eye Drops Market– By Drug Type
10.1.1. Beta Blockers
10.1.2. Alpha Agonists
10.1.3. Carbonic Anhydrase Inhibitors
10.1.4. Prostaglandin analogs
10.1.5. Combined medications
10.1.6. Others
10.2. Europe Glaucoma Eye Drops Market– By Disease
10.2.1. Open Angle Glaucoma
10.2.2. Angle Closure Glaucoma
10.3. Europe Glaucoma Eye Drops Market– By Sales Channel
10.3.1. Online
10.3.2. Retail
10.3.3. Hospital Pharmacy
10.4. Europe Glaucoma Eye Drops Market– By Country
10.4.1. Germany
10.4.2. France
10.4.3. UK
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
Chapter 11. Asia Pacific Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
11.1. Asia Pacific Glaucoma Eye Drops Market– By Drug Type
11.1.1. Beta Blockers
11.1.2. Alpha Agonists
11.1.3. Carbonic Anhydrase Inhibitors
11.1.4. Prostaglandin analogs
11.1.5. Combined medications
11.1.6. Others
11.2. Asia Pacific Glaucoma Eye Drops Market– By Disease
11.2.1. Open Angle Glaucoma
11.2.2. Angle Closure Glaucoma
11.3. Asia Pacific Glaucoma Eye Drops Market– By Sales Channel
11.3.1. Online
11.3.2. Retail
11.3.3. Hospital Pharmacy
11.4. Asia-Pacific Glaucoma Eye Drops Market– By Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Rest of Asia-Pacific
Chapter 12. Latin America Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
12.1. Latin America Glaucoma Eye Drops Market– By Drug Type
12.1.1. Beta Blockers
12.1.2. Alpha Agonists
12.1.3. Carbonic Anhydrase Inhibitors
12.1.4. Prostaglandin analogs
12.1.5. Combined medications
12.1.6. Others
12.2. Latin America Glaucoma Eye Drops Market– By Disease
12.2.1. Open Angle Glaucoma
12.2.2. Angle Closure Glaucoma
12.3. Latin America Glaucoma Eye Drops Market– By Sales Channel
12.3.1. Online
12.3.2. Retail
12.3.3. Hospital Pharmacy
12.4. Latin America Glaucoma Eye Drops Market– By Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
Chapter 13. Middle East & Africa Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
13.1. Middle East & Africa Glaucoma Eye Drops Market– By Drug Type
13.1.1. Beta Blockers
13.1.2. Alpha Agonists
13.1.3. Carbonic Anhydrase Inhibitors
13.1.4. Prostaglandin analogs
13.1.5. Combined medications
13.1.6. Others
13.2. Middle East & Africa Glaucoma Eye Drops Market– By Disease
13.2.1. Open Angle Glaucoma
13.2.2. Angle Closure Glaucoma
13.3. Middle East & Africa Glaucoma Eye Drops Market– By Sales Channel
13.3.1. Online
13.3.2. Retail
13.3.3. Hospital Pharmacy
13.4. Middle East & Africa Glaucoma Eye Drops Market– By Country
13.4.1. UAE
13.4.2. Saudi Arabia
13.4.3. Turkey
13.4.4. Rest of Middle East & Africa
Chapter 14. Competitive Analysis
14.1.1. Competition Dashboard
14.1.2. Company Profiles
14.1.2.1. Merck & Co., Inc.,
14.1.2.2. Allergan Plc.
14.1.2.3. Novartis AG.
14.1.2.4. Teva Pharmaceutical Industry
14.1.2.5. Pfizer, Inc.
14.1.2.6. Bausch & Lomb Inc.
14.1.2.7. Inotek Pharmaceutical
14.1.2.8. Jadran-galenski laboratorij d.d.
14.1.2.9. Aerie Pharmaceutical
14.1.2.10. Mylan N.V.
Increasing awareness of glaucoma and rising demand for drugs made for the treatment of glaucoma are some of the major trends that can be observed in the global glaucoma eye drops market. Glaucoma can be majorly seen in people above the age of 40 and it may be asymptomatic. According to a recent survey by Glaucoma Research Foundation, 74% of over 1,000 people interviewed said they have their eyes examined at least every two years. 61% of those (less than half of all adult Americans) are receiving a dilated eye exam (the best and most effective way to detect glaucoma). 16% of African Americans were unfamiliar with glaucoma. 9% of Caucasians were unfamiliar with glaucoma.
A few novel glaucoma eye drops have been affirmed by administrative bodies in various nations and significant players in the market have propelled different novel and inventive glaucoma eye drops. Quick endorsements and dispatches of novel products in the market are relied upon to be a significant driver for the development of the glaucoma eye drops market. For instance, in March 2019, the U.S. Food and Drug Administration (USFDA) approved Aerie Pharmaceuticals’ Rocklatan a netarsudil and latanoprost ophthalmic solution for the treatment of open-angle glaucoma.
Nevertheless, glaucoma is a sickness that can’t be cured, yet it tends to be controlled. Eye drops, pills, laser strategies, and surgeries are utilized to forestall or slow further harm from happening. Glaucoma is an irreversible sickness, and the broad R&D exercises make the medication over the top expensive which is anticipated to hamper the glaucoma eye drops market growth during the years to come.
The global glaucoma eye drops market size was esteemed at USD 1.2 billion in 2019 and is anticipated to expand at a CAGR of 6.5% during the forecast period 2019-2028. The rising prevalence and incidence of eye-related diseases are major factor proliferating the growth of glaucoma eye drops market. Glaucoma cases are up surging every year across the globe and account for over 10 million visits to physicians every year. According to world health organization (WHO), glaucoma is the second most common cause of blindness worldwide with more than 70 million people affected by it, and this figure is expected to grow to 111 million by 2040. The most common type of glaucoma are primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). According to world health organization (WHO), glaucoma is responsible for approximately 5 million blind which is 15% of total world blindness.
The global glaucoma eye drops market is anticipated to grow significantly on the back of a high number of populations are impacted by this, and increasing number of cases worldwide. The rising government initiatives and drug approvals for prevention of glaucoma-related blindness are further bolstering the growth of the global glaucoma eye drops market. The market for glaucoma eye drops is projected to cross US$ 6 billion by 2028.
Based on disease perspective in glaucoma eye drops industry, glaucoma eye drops can be classified into open-angle glaucoma and angle-closure glaucoma. In 2019, open-angle glaucoma was the most common for contributing more than 80% of market revenue. According to American Academy of Ophthalmology, Primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness worldwide. This is anticipated to bolster the growth of the segment.
In addition, according to American Academy of Ophthalmology, a hospital-based survey of glaucoma in Ghana reported that the most common form of glaucoma was primary open-angle glaucoma (44.2%). People in their 70s have a 3 to 8 times higher prevalence of POAG. As the population ages, the total number of glaucoma patients will continue to rise.
North America dominated the global glaucoma eye drops market accounting for a market share of more than 30% of market revenue. This can be attributed to rising number of glaucoma cases and increasing number of product launches for its treatment. For instance, According to a recent study, more than 3 million Americans are living with glaucoma, 2.7 million of those—aged 40 and more—are affected by its most common form, open-angle glaucoma. Blindness or low vision affects 3.3 million Americans age 40 and over. Glaucoma costs the U.S. economy $2.86 billion every year in direct costs and productivity losses.
Asia Pacific region is anticipated to register fastest growth during the forecast period. This can be associated with rising prevalence of glaucoma in the region with more than 90% of cases remaining undiagnosed. For instance, according to world health organization, In India, glaucoma is the leading cause of irreversible blindness with at least 12 million people affected, and nearly 1.2 million people blind from the disease.
Noticeable players within the market are
The players of glaucoma eye drops industry are focusing majorly on developing and launching more advanced products with more features to gain a competitive edge in the market. Strategies such as partnerships, new product development, licensing agreements, and other legally binding agreements are being reported by major players to become the market leader. For instance, in June 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension.
This report bifurcates glaucoma eye drops revenue opportunities at worldwide, territorial, and national levels and gives an investigation of the most recent industry patterns in each of the sub-segments during the estimated period. For the reason of this ponder, Alchemy Market Research has sectioned the worldwide glaucoma eye drops market report on the premise of drug type strategy, disease strategy, sales channel strategy, and regional analysis:
Drug Type Perspective (Revenue in USD Billion)
Disease Perspective (Revenue in USD Billion)
Sales Channel Perspective (Revenue in USD Billion)
Regional Perspective (Revenue in USD Billion)
Chapter 1. Executive Summary
Chapter 2. Market Introduction
Chapter 3. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints
Chapter 4. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
Chapter 5. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Drug Type
5.1. Beta Blockers
5.2. Alpha Agonists
5.3. Carbonic Anhydrase Inhibitors
5.4. Prostaglandin analogs
5.5. Combined medications
5.6. Others
Chapter 6. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Disease
6.1. Open Angle Glaucoma
6.2. Angle Closure Glaucoma
Chapter 7. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Sales Channel
7.1. Online
7.2. Retail
7.3. Hospital Pharmacy
Chapter 8. Global Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028 – By Region
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. Latin America
8.5. Middle East & Africa
Chapter 9. North America Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
9.1. North America Glaucoma Eye Drops Market– By Drug Type
9.1.1. Beta Blockers
9.1.2. Alpha Agonists
9.1.3. Carbonic Anhydrase Inhibitors
9.1.4. Prostaglandin analogs
9.1.5. Combined medications
9.1.6. Others
9.2. North America Glaucoma Eye Drops Market– By Disease
9.2.1. Open Angle Glaucoma
9.2.2. Angle Closure Glaucoma
9.3. North America Glaucoma Eye Drops Market– By Sales Channel
9.3.1. Online
9.3.2. Retail
9.3.3. Hospital Pharmacy
9.4. North America Glaucoma Eye Drops Market– By Country
9.4.1. U.S.
9.4.2. Canada
Chapter 10. Europe Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
10.1. Europe Glaucoma Eye Drops Market– By Drug Type
10.1.1. Beta Blockers
10.1.2. Alpha Agonists
10.1.3. Carbonic Anhydrase Inhibitors
10.1.4. Prostaglandin analogs
10.1.5. Combined medications
10.1.6. Others
10.2. Europe Glaucoma Eye Drops Market– By Disease
10.2.1. Open Angle Glaucoma
10.2.2. Angle Closure Glaucoma
10.3. Europe Glaucoma Eye Drops Market– By Sales Channel
10.3.1. Online
10.3.2. Retail
10.3.3. Hospital Pharmacy
10.4. Europe Glaucoma Eye Drops Market– By Country
10.4.1. Germany
10.4.2. France
10.4.3. UK
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
Chapter 11. Asia Pacific Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
11.1. Asia Pacific Glaucoma Eye Drops Market– By Drug Type
11.1.1. Beta Blockers
11.1.2. Alpha Agonists
11.1.3. Carbonic Anhydrase Inhibitors
11.1.4. Prostaglandin analogs
11.1.5. Combined medications
11.1.6. Others
11.2. Asia Pacific Glaucoma Eye Drops Market– By Disease
11.2.1. Open Angle Glaucoma
11.2.2. Angle Closure Glaucoma
11.3. Asia Pacific Glaucoma Eye Drops Market– By Sales Channel
11.3.1. Online
11.3.2. Retail
11.3.3. Hospital Pharmacy
11.4. Asia-Pacific Glaucoma Eye Drops Market– By Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Rest of Asia-Pacific
Chapter 12. Latin America Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
12.1. Latin America Glaucoma Eye Drops Market– By Drug Type
12.1.1. Beta Blockers
12.1.2. Alpha Agonists
12.1.3. Carbonic Anhydrase Inhibitors
12.1.4. Prostaglandin analogs
12.1.5. Combined medications
12.1.6. Others
12.2. Latin America Glaucoma Eye Drops Market– By Disease
12.2.1. Open Angle Glaucoma
12.2.2. Angle Closure Glaucoma
12.3. Latin America Glaucoma Eye Drops Market– By Sales Channel
12.3.1. Online
12.3.2. Retail
12.3.3. Hospital Pharmacy
12.4. Latin America Glaucoma Eye Drops Market– By Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
Chapter 13. Middle East & Africa Glaucoma Eye Drops Market– Analysis and Revenue Forecast 2019-2028
13.1. Middle East & Africa Glaucoma Eye Drops Market– By Drug Type
13.1.1. Beta Blockers
13.1.2. Alpha Agonists
13.1.3. Carbonic Anhydrase Inhibitors
13.1.4. Prostaglandin analogs
13.1.5. Combined medications
13.1.6. Others
13.2. Middle East & Africa Glaucoma Eye Drops Market– By Disease
13.2.1. Open Angle Glaucoma
13.2.2. Angle Closure Glaucoma
13.3. Middle East & Africa Glaucoma Eye Drops Market– By Sales Channel
13.3.1. Online
13.3.2. Retail
13.3.3. Hospital Pharmacy
13.4. Middle East & Africa Glaucoma Eye Drops Market– By Country
13.4.1. UAE
13.4.2. Saudi Arabia
13.4.3. Turkey
13.4.4. Rest of Middle East & Africa
Chapter 14. Competitive Analysis
14.1.1. Competition Dashboard
14.1.2. Company Profiles
14.1.2.1. Merck & Co., Inc.,
14.1.2.2. Allergan Plc.
14.1.2.3. Novartis AG.
14.1.2.4. Teva Pharmaceutical Industry
14.1.2.5. Pfizer, Inc.
14.1.2.6. Bausch & Lomb Inc.
14.1.2.7. Inotek Pharmaceutical
14.1.2.8. Jadran-galenski laboratorij d.d.
14.1.2.9. Aerie Pharmaceutical
14.1.2.10. Mylan N.V.
